REG - Medpal AI PLC - Launch of MedPal Health OS

Medpal AIAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260408:nRSH5218Za&default-theme=true

RNS Number : 5218Z  Medpal AI PLC  08 April 2026

8 April 2026

 

MedPal AI plc

("MedPal AI" or the "Company")

 

Technology Platform Update

Launch of the MedPal Health OS

 

MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health
company, is pleased to provide an update on its technology platform strategy
and the launch of the MedPal Health Operating System ("OS").

 

Highlights:

•     MedPal Health OS: The Company is introducing the MedPal Health OS,
a vertically integrated, closed-loop digital health platform combining
wearable data, AI triage, clinician-led prescribing, and robotic dispensing -
designed to make personalised, data-driven healthcare accessible to every
person in the UK at ultra-low cost

•     First of its kind: The Directors believe the MedPal Health OS is
the first closed-loop digital health operating system of its kind in the
United Kingdom

•     100+ wearable integrations: The MedPal AI app can aggregate
real-time physiological data from over 100 wearable devices and health apps to
establish areal-time, data-rich health profile for each user

•     End-to-end integration: The platform connects wearable data to AI
triage, clinician-led prescribing and robotic dispensing in a single
continuous data loop, enabling personalised healthcare at scale

 

The MedPal Health OS - Closing the Bio-Feedback Loop

 

The MedPal Health OS integrates every stage of the patient health journey into
a single, continuous data loop. The MedPal AI app aggregates real-time
physiological data from over 100 wearable devices and health apps, including
Apple Health, Whoop, and Garmin, to establish a real-time, data-rich health
profile for each user. This "biological truth" is processed by the Company's
clinician-trained AI, which generates personalised health scores and flags
potential interventions. Where clinical action is indicated, the platform
enables AI-assisted diagnosis supported by expert clinician review and
data-backed prescribing. Medications are then fulfilled through the Company's
BD Rowa VMAX robotic dispensing infrastructure at over 200 items per hour with
99.99% accuracy. Critically, once medication is delivered, the resulting
physiological changes are tracked back into the wearable data layer, closing
the loop and continuously refining each patient's health profile. The
Company's recently announced at-home blood test kits further strengthen this
bio-feedback loop, enabling users to layer clinical-grade biomarker data
alongside real-time wearable inputs such as heart rate, sleep, and activity
tracking for a more complete and actionable health profile.

 

The MedPal AI app sits at the centre of this platform. It is the front door
through which millions of consumers can access the Health OS, transforming a
smartphone into a personal health command centre. The app's ability to unify
fragmented wearable data into a single actionable profile is a critical
differentiator: it replaces the siloed model of traditional healthcare with a
continuous, data-driven approach. The Board believes the app represents a
significant strategic asset, both as a direct-to-consumer engagement channel
and as the data engine powering the Company's clinical and pharmacy services.

 

The Directors believe the MedPal Health OS represents a fundamental shift from
the reactive, episodic model of traditional pharmacy,where data is siloed, GP
waits can exceed two weeks, and manual dispensing carries error rates of up to
2%, to a proactive, always-on system where data drives the medication and
medication improves the data. The platform is designed to be accessible to
every person in the UK at ultra-low cost, leveraging the Company's automated
infrastructure to deliver personalised healthcare at scale.

 

Outlook

The Board is confident in the strategic significance of the MedPal Health OS
as a platform for long-term growth. Key drivers of adoption and commercial
opportunity include:

 

•     Health OS adoption: Roll-out of the MedPal Health OS platform to
drive user engagement, clinical outcomes and long-term recurring revenue
through the Company's integrated app, clinical, and pharmacy ecosystem

•     Epassi partnership: Exclusive, zero-cost access to the MedPal AI
app across Epassi's network of over 11 million employees provides a
substantial acquisition channel for Health OS users

•     B2B licensing: The Company plans to expand via B2B licensing to
healthcare providers, businesses, and insurers, with potential use in
insurance-linked wellness programmes

•     Data-driven competitive advantage: The closed-loop architecture
continuously improves patient outcomes and deepens the Company's proprietary
data asset, creating compounding differentiation over time

 

Jason Drummond, Chief Executive Officer of MedPal AI, commented:

"With the introduction of the MedPal Health OS, we are now articulating what
we have been building from the outset: a closed-loop digital health platform
that connects wearable data to AI triage to clinician-led prescribing to
robotic dispensing and back again. Data drives the medication, and the
medication improves the data. As far as we are aware, no other company in the
UK is providing this end to end service.

"Our app is the key that unlocks this for millions of people. It turns a
smartphone into a personal health operating system-accessible to everyone at a
fraction of the cost of typical private healthcare. Combined with our pharmacy
infrastructure, it gives us a platform that scales revenue while genuinely
improving patient outcomes.

"The traditional pharmacy model is being disrupted, and MedPal is leading that
disruption. We look forward to updating the market on continued progress."

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer         Via Square1 Consulting

 Cairn Financial Advisers LLP                    +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited                   +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                              +44 (0) 20 7929 5599

 David Bick                                      +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company building the MedPal Health OS -
a vertically integrated, closed-loop platform spanning AI wellness, clinical
services, and automated pharmacy fulfilment. Its core app aggregates data from
over 100 wearable devices and health apps (including Apple Health, Fitbit,
Garmin, and Whoop) into a unified health profile, offering personalised,
non-clinical lifestyle guidance through its AI wellness coach and acting as
the consumer front door to the Company's clinical and pharmacy services.

 

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages BD Rowa VMAX
robotic dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

 

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms. The Company's LEI is
984500EDP8B0A14CBA61.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STREASLXESPKEFA



            Copyright 2019 Regulatory News Service, all rights reserved